Low
₹2,462.20
High
₹2,562.80
| Previous Close | ₹2,551.00 |
|---|---|
| Day's Range | ₹2,462.20 - ₹2,562.80 |
| Open | ₹2,498.90 |
| 52 Week Range | ₹2,088.10 - ₹3,220.00 |
| Volume | 80,758 |
| Market Cap | ₹0.04 |
| Previous Close | ₹2,550.00 |
|---|---|
| Day's Range | ₹2,463.95 - ₹2,562.00 |
| Open | ₹2,503.95 |
| 52 Week Range | ₹2,088.00 - ₹3,217.10 |
| Volume | 4,175 |
| Market Cap | ₹0.04 |
| Trade Value ( ₹ in Lacs) | 2,060.14 |
|---|---|
| Market Cap (₹ in Mn) | 0.04 |
| Dividend Yield(%) | 2.28 |
| Price/Earning (TTM) | 40.97 |
| TTM EPS (₹) | 61.15 |
| P/E Ratio | 37.34 |
| Book Value(₹) | 18.59 |
| PAT Margin (%) | 24.54 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 66.79 |
| Trade Value ( ₹ in Lacs) | 106.46 |
|---|---|
| Market Cap (₹ in Mn) | 0.04 |
| Dividend Yield(%) | 2.28 |
| Price/Earning (TTM) | 40.97 |
| TTM EPS (₹) | 61.15 |
| P/E Ratio | 37.34 |
| Book Value(₹) | 18.59 |
| PAT Margin (%) | 24.54 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 66.79 |
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 37234.9 | 9743.7 |
| Expenses | N/A | N/A |
| PBT | 12484.4 | 3585.7 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 9190.6 | 2628.7 |
| Founded | 1924 |
|---|---|
| Managing Director | Bhushan Akshikar |
| NSE Symbol | GLAXO |
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,70,785.51 | 1,939.50 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,94,589.80 | 7,366.05 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,91,657.85 | 4,996.00 | 3,468.00 - 3,468.00 |
| Apollo Hospitals Enterprise Ltd. | 1,28,264.54 | 8,920.50 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,15,727.88 | 1,412.00 | 1,165.70 - 1,165.70 |
| Lupin Ltd. | 1,14,967.14 | 2,415.55 | 1,836.80 - 1,836.80 |
| Zydus Lifesciences Ltd. | 1,14,079.53 | 1,120.50 | 835.50 - 835.50 |
| Max Healthcare Institute Ltd. | 1,07,094.14 | 1,082.00 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,06,460.04 | 2,538.65 | 1,909.70 - 1,909.70 |
| Dr. Reddy's Laboratories Ltd. | 1,00,707.81 | 1,182.30 | 1,148.40 - 1,148.40 |
No Records Found
Pursuant to Regulations 29 & 33 of the Listing Obligations and Disclosure Requirements Regulations, 2015 (LODR), GlaxoSmithKline Pharmaceuticals has informed that a meeting of the Board of Directors of our Company will be held on Monday, 3rd August 2026, to consider, approve and take on record the Un-audited financial results for the first quarter ended 30th June 2026.
The above information is a part of company’s filings submitted to BSE.
Pursuant to regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Granules India has informed that the audio recording of the earnings conference call of the Company for the Q1 of FY27 has been uploaded on the website of the Company at the below-mentioned link: https://granulesindia.com/investors/investor-resources/earnings-call-recording/.
The above information is a part of company’s filings submitted to BSE.
No Records Found
The current share price of Glaxosmithkline Pharmaceuticals Ltd. is ₹2,551.00 as of 2026-07-22.
The market capitalisation of Glaxosmithkline Pharmaceuticals Ltd. is ₹42,441.29 as of 2026-07-21.
The 1-year return of Glaxosmithkline Pharmaceuticals Ltd. is -568.10% as of 2026-07-22.
The P/E ratio of Glaxosmithkline Pharmaceuticals Ltd. is 37.34 as of 2026-07-22.
The 52-week high and low of Glaxosmithkline Pharmaceuticals Ltd. are ₹3,220.00 and ₹2,088.10, respectively, as of 2026-07-22.
GlaxoSmithKline Pharmaceuticals Ltd. forms partnerships by collaborating with medical professionals and government health agencies to promote mass immunisation and disease awareness. The company ensures a robust supply chain to deliver life-saving medicines consistently to hospitals and regional clinics.
GlaxoSmithKline Pharmaceuticals Ltd. offers an important range of prescription medicines and preventative vaccines. The company focuses heavily on anti-infectives, dermatology, pediatric vaccines, and general medicines, supplying highly trusted pharmaceutical brands to the Indian healthcare system.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.